Nury Steuerwald

12PUBLICATIONS
44CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersBiomechanicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Feb 20, 2026
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Shebli Atrash, James Symanowski, Myra Robinson

|Nov 14, 2025
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Mohamed E Salem, Alberto Puccini, Elizabeth Mauer

|Jan 08, 2025
Immunophenotyping of Synovial Tissue in Adolescents Undergoing ACL Reconstruction: What Is the Role of Synovial Inflammation in Arthrofibrosis?

Sarah M Romereim, Matthew R Smykowski, Elaina K Ball

|Nov 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Manisha Bhutani, Myra Robinson, David Foureau

|Oct 07, 2024
High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following Transplant.

Samantha M Short, Mildred D Perez, Alexis E Morse

|May 20, 2024
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.

Kirk D Beebe, Joel R Eisner, John Guo

Pageof 2

Frequent Collaborators

3 joint publications

Peter M Voorhees

2 joint publications

Mario Cuadra

2 joint publications

Yuelong Guo

2 joint publications

Carol Farhangfar